The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights. Q1 ...

Edwards Lifesciences reports 8% Q1 2025 sales growth to $1.41B, driven by TAVR & TMTT. Discover regulatory catalysts & future growth insights.

Edwards Lifesciences Corp (EW) reports an 8% increase in total sales, raises full-year guidance, and achieves significant ...

General Hospital (GH) in Ernakulam prepares for first heart transplant surgery in May, following successful cardiac care initiatives.

Vivasure hope to find room in a competitive market with its surtureless implant that is absorbed 180 days after vessel ...

Edwards Lifesciences Corporation ( NYSE: EW) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - ...

Tariff talk will continue in the second week of earnings season, but the updates could also shed light on trends and ...

Canaccord analyst William Plovanic raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $71. The firm said Edwards delivered ...

Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

Edwards Lifesciences (NYSE: EW) shares stayed put after hours today on first-quarter results that beat Wall Street ...

Edwards Lifesciences raised 2025 revenue forecast after Q1 results beat EPS estimates and TMTT sales jumped 58% amid strong ...